PATENT CLAIM ANALYSIS

Application Number: 16238346
Application Type: Utility
Filing Date: 2019-01
Publication Date: 2019-05
Patent Classification: ["514", "023000"]

Abstract:
The invention relates to novel liquid pharmaceutical compositions comprising at least one SGLT-2 inhibitor and one or more polar organic solvents, wherein the at least one SGLT-2 inhibitor comprises 1-cyano-2-(4-cyclopropyl-benzyl)-4-(β-D-glucopyranos-1-yl)-benzene according to formula (I): as well as corresponding processes of manufacturing such liquid pharmaceutical compositions and their medical uses.

Claim (Index 15):
The liquid pharmaceutical composition according to  claim 1  for use in a method for treating or preventing medicinal indications in a mammal in need of such treatment or prevention selected from among the medicinal indications:\n (i) a metabolic disorder of an equine animal, wherein the metabolic disorder is selected from the group consisting of: insulin resistance, hyperinsulinemia, impaired glucose tolerance, dyslipidemia, dysadipokinemia, subclinical inflammation, systemic inflammation, low grade systemic inflammation, obesity, regional adiposity, and mixtures thereof; \n (ii) a metabolic disorder of an equine animal, wherein the metabolic disorder is selected from the group consisting of: laminitis, vascular dysfunction, hypertension, hepatic lipidosis, atherosclerosis, hyperadrenocorticism, Pituitary Pars Intermedia Dysfunction, Equine Metabolic Syndrome and mixtures thereof, \n (iii) a metabolic disorder of a feline animal, wherein the metabolic disorder is selected from the group consisting of: ketoacidosis, pre-diabetes, diabetes mellitus type 1 or type 2, insulin resistance, obesity, hyperglycemia, impaired glucose tolerance, hyperinsulinemia, dyslipidemia, dysadipokinemia, subclinical inflammation, systemic inflammation, low grade systemic inflammation, hepatic lipidosis, atherosclerosis, inflammation of the pancreas, neuropathy, Syndrome X (metabolic syndrome), loss of pancreatic beta cell function and mixtures thereof; \n (iv) a metabolic disorder of a canine animal, wherein the metabolic disorder is selected from the group consisting of: ketoacidosis, pre-diabetes, insulin dependent diabetes mellitus, insulin resistance diabetes, insulin resistance, obesity, hyperglycemia, hyperglycemia induced cataract formation, impaired glucose tolerance, hyperinsulinemia, dyslipidemia, dysadipokinemia, subclinical inflammation, systemic inflammation, low grade systemic inflammation, hepatic lipidosis, inflammation of the pancreas, metabolic disorder consequences, such as hypertension, renal dysfunction, musculoskeletal disorders, Syndrome X (metabolic syndrome), and mixtures thereof.

Metadata:
- Claim Count in Document: 2.0
- Percentile: 99.0
- Lexical Diversity: 1.34783
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['15245448', '15113127', '14573352', '14672705', '15512984']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8588589898501255
- 35 USC 102 Novelty (BERT): 0.6691226469480848
- Combined Prediction Score: 0.8398853555599215
- Mean Citation Score: 464.385204
- Max Citation Score: 657.3167
- Similarity Product: 572.2722898454666

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test